Right Heart Remodeling in Patients with End-Stage Alcoholic Liver Cirrhosis: Speckle Tracking Point of View.

BACKGROUND: Data regarding cardiac remodeling in patients with alcoholic liver cirrhosis are scarce. We sought to investigate right atrial (RA) and right ventricular (RV) structure, function, and mechanics in patients with alcoholic liver cirrhosis. METHODS: This retrospective cross-sectional investigation included 67 end-stage cirrhotic patients, who were referred for evaluation for liver transplantation and 36 healthy controls. All participants underwent echocardiographic examination including strain analysis, which was performed offline. RESULTS: RV basal diameter and RV thickness were significantly higher in patients with cirrhosis. Conventional parameters of the RV systolic function were similar between the observed groups. Global, endocardial, and epicardial RV longitudinal strains were significantly lower in patients with cirrhosis. Active RA function was significantly higher in cirrhotic patients than in controls. The RA reservoir and conduit strains were significantly lower in cirrhotic patients, while there was no difference in the RA contractile strain. Early diastolic and systolic RA strain rates were significantly lower in cirrhotic patients than in controls, whereas there was no difference in the RA late diastolic strain rate between the two groups. Transaminases and bilirubin correlated negatively with RV global longitudinal strain and RV-free wall strain in patients with end-stage liver cirrhosis. The Model for End-stage Liver Disease (MELD) score, predictor of 3-month mortality, correlated with parameters of RV structure and systolic function, and RA active function in patients with end-stage liver cirrhosis. CONCLUSIONS: RA and RV remodeling is present in patients with end-stage liver cirrhosis even though RV systolic function is preserved. Liver enzymes, bilirubin, and the MELD score correlated with RV and RA remodeling.

Vascular Anomalies of the Extrahepatic Artery as a Predictable Risk Factor for Complications After Liver Transplant.

OBJECTIVES: Vascular variations of the extrahepatic artery occur in up to 50% of the population. Exact knowledge of any anomalies is of great significance in hepatobiliary surgery to avoid perioperative complications. In fact, in liver transplant, vascular complications are rare but have a major impact on graft function and survival. This study evaluated variations of the extrahepatic artery in donors and recipients as risk factors for vascular complications after liver transplant. MATERIALS AND METHODS: From January 2010 until June 2015, 469 liver transplant procedures were performed at our institution. We included 323 patients in our retrospective analysis after exclusion of retransplants, split-livertransplants, and pediatric patients. We analyzed the impact of anatomic variations of recipients and donors on postoperative vascular complications and organ and patient survival. RESULTS: Of total study recipients, 71.2% had a normal vascular supply according to Michel classification I. However, these patients developed significantly more vascular complications (25.65%) than those with vascular anomalies (15.05%), especially showing higher incidence of arterial stenosis (8.26% vs 2.15%). In contrast, vascular variations in donors and the need for a vascular reconstruction of the graft led to significantly higher mortality (26.76% vs 15.48%). An abnormality of the graft did not influence incidence of postoperative complications or graft survival. CONCLUSIONS: Unexpectedly, recipients with variations of the hepatic artery and grafts with an abnormal arterial supply did not show higher rates of com-plications or mortality. Only vascular reconstruction of the graft before transplant raised the mortality of recipients.

Evaluation of histological dynamics, kidney function and diabetes in liver transplant patients after antiviral treatment with direct-acting antivirals: Therapy of HCV-recurrence.

BACKGROUND: Direct-acting antivirals allow efficient and safe treatment of hepatitis C (HCV) before and after liver transplantation (LT). However, the impact of sofosbuvir on the graft, diabetes, and on kidney function is not answered yet. Primary endpoint of this analysis was the evaluation of kidney function after antiviral treatment (AVT). Secondary endpoints were the assessment of extrahepatic manifestation of HCV-infection by diabetes mellitus and the histopathological changes in terms of inflammation, content of fat, and fibrosis stage. METHODS: From 2014 to 4/2015, 100 patients with HCV-recurrence after LT were successfully treated with AVT. Ninety-eight received a sofosbuvir-based regimen. Indication was based on genotype, transplant fibrosis stage, and urgency. Biopsies were evaluated before and after treatment. Renal function and diabetes were assessed before, during, and after AVT. RESULTS: All patients achieved sustained virological response. A significant improvement of inflammation (P = 0.001) and fibrosis stage (P = 0.031) were observed. Significantly less insulin was required in 32 patients with diabetes (P < 0.001) to keep Hb1Ac unchanged after AVT. Kidney function was stable during, 12 weeks after and 48 weeks after antiviral therapy. Stages of renal insufficiency were comparable before and after AVT. CONCLUSION: Successful sofosbuvir-based AVT leads to a variety of positive development in transplant patients including a significant improvement of inflammation, fat content and fibrosis, a significant decrease in daily insulin dose and no significant impairment of kidney function.

Adrenal Metastasis of Hepatocellular Carcinoma in Patients following Liver Resection or Liver Transplantation: Experience from a Tertiary Referral Center.

INTRODUCTION: Adrenal metastasis of hepatocellular carcinoma (HCC) is a rare entity and can be treated by resection, local ablative therapy, or systemic therapy. Unfortunately, data about treatment outcome, especially in liver transplant recipients, are rare. PATIENTS AND METHODS: From 2005 to 2015, 990 liver resections and 303 liver transplantations because of HCC were performed at our clinic. We retrospectively analyzed treatment outcome of the patients with metachronous adrenal metastasis of HCC, who received either resection, local ablation, or surveillance only. RESULTS: 10 patients were identified (0.8%). 7 patients received liver transplantation for primary HCC therapy, 3 liver resection, and 1 a local ablative therapy. 8 patients underwent adrenalectomy (one via retroperitoneoscopy), one was treated with local ablation, and one had surveillance only. Seven out of eight patients had no surgical complications and one experienced a pancreatic fistula, treated conservatively. 37.5% of the resected patients had recurrence 1 year after adrenalectomy and 75% after 2 years. The mean survival time after primary diagnosis of HCC was 96.6±22.4 months. After adrenalectomy, the mean survival time was 112.4±25.2 months. The mean time until tumor recurrence was 13.2±3.8 in the total cohort and 15.8±3.8 months in patients after adrenalectomy. The estimated overall survival after adrenalectomy was 77.2±17.4 months. CONCLUSION: Metachronous adrenal metastasis occured in less than 1% of HCC patients. Adrenalectomy is a safe procedure and leads to acceptable survival rates even after liver transplantion. Therefore, it should be performed whenever the primary tumor is well controlled and the patient is in adequate physical condition.

Impact of Doppler Ultrasound on Diagnosis and Therapy Control of Lienalis Steal Syndrome After Liver Transplantation.

BACKGROUND Lienalis steal syndrome is a rare complication after orthotopic liver transplantation leading to severe complications. Routine duplex sonography allows early and safe detection of lienalis steal syndrome and secondarily helps to monitor the outcome by evaluating the hemodynamics. MATERIAL AND METHODS This analysis included eight patients who after orthotopic liver transplantation needed splenic artery embolization due to lienalis steal syndrome. Lienalis steal syndrome was assumed in case of elevated transaminases, bilirubinemia or persistent ascites, and the absence of further pathologies. Diagnosis was supported by ultrasound, confirmed by digital subtraction angiography, and followed by splenic artery embolization for treatment. We analyzed blood levels and ultrasound findings before and after splenic artery embolization as well as during follow-up and evaluated for incidence of severe biliary complications and survival. RESULTS Arterial resistive index (RI) significantly regularized after splenic artery embolization while the maximum arterial velocity increased. The portal venous flow volume and maximum velocity decrease. Laboratory parameters normalized. Two of eight patients developed ischemic-type biliary disease. Survival rate was 88% over a median follow-up of 33 months. CONCLUSIONS Beside unspecific clinical findings, bedside ultrasound examination enabled a quick verification of the diagnosis and allowed direct treatment to minimize further complications. Furthermore, ultrasound can immediately monitor the therapeutic effect of splenic artery embolization.